AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study by Dummer, R, Robert, C, Chapman, P, Sosman, J, Middleton, M, Bastholt, L, Kemsley, K, Cantarini, M, Morris, C, Kirkwood, J

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. by Kirkwood, J, Bastholt, L, Robert, C, Sosman, J, Larkin, J, Hersey, P, Middleton, M, Cantarini, M, Zazulina, V, Kemsley, K, Dummer, R

Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines by Peris, K, Fargnoli, MC, Garbe, C, Kaufmann, R, Bastholt, L, Seguin, NB, Bataille, V, Marmol, VD, Dummer, R, Harwood, CA, Hauschild, A, Höller, C, Haedersdal, M, Malvehy, J, Middleton, MR, Morton, CA, Nagore, E, Stratigos, AJ, Szeimies, RM, Tagliaferri, L, Trakatelli, M, Zalaudek, I, Eggermont, A, Grob, JJ, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC)